Evolva Holding SA today announced that Dr. Melya Hughes Crameri, CEO of Evolva’s US subsidiary Genetic Chemistry, has resigned from her role effective June 18th, in order to pursue other opportunities. Dr. Panchapagesa Murali, CEO of Evolva’s Indian subsidiary, will serve as acting CEO of Evolva’s US operations until a successor is named.
Neil Goldsmith, CEO and Managing Director of Evolva Holding SA commented, “Melya has been an integral part of the management team over the past five years. On behalf of the Board and the Evolva team, we extend our gratitude to Melya for her contributions and wish her the best in her future endeavours.”
Mr. Murali has over 20 years experience in pharmaceutical and healthcare R&D. He has led Evolva’s Indian operations since September 2006 and is a member of the Group Management Team of Evolva Holding SA.
For more information, please click the link below:
Evolva Holding SA